Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.

[1]  M. White,et al.  Protein binding and signaling properties of RIN1 suggest a unique effector function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Baltimore,et al.  Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok , 1997, Cell.

[3]  R. Kobayashi,et al.  p62 dok : A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells , 1997, Cell.

[4]  M. Schwartz,et al.  Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. T. Brown,et al.  Regulation, substrates and functions of src. , 1996, Biochimica et biophysica acta.

[6]  D. Baltimore,et al.  Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin. , 1996, Genes & development.

[7]  R. Gentz,et al.  Grap Is a Novel SH3-SH2-SH3 Adaptor Protein That Couples Tyrosine Kinases to the Ras Pathway (*) , 1996, The Journal of Biological Chemistry.

[8]  J. Blenis,et al.  The 70 kDa S6 Kinase Complexes with and Is Activated by the Rho Family G Proteins Cdc42 and Rac1 , 1996, Cell.

[9]  R. V. van Etten,et al.  The cytostatic function of c‐Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. , 1996, The EMBO journal.

[10]  M. Roussel,et al.  Signaling by ABL oncogenes through cyclin D1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  O. Witte,et al.  Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene , 1995, Cell.

[12]  P. Laneuville.  Abl tyrosine protein kinase. , 1995, Seminars in immunology.

[13]  M. Roussel,et al.  Rescue of defective mitogenic signaling by D-type cyclins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Baltimore,et al.  Proline-rich sequences that bind to Src homology 3 domains with individual specificities. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Colicelli,et al.  A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1 , 1995, Molecular and cellular biology.

[16]  Tony Pawson,et al.  Protein modules and signalling networks , 1995, Nature.

[17]  C. Sawyers,et al.  Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene , 1995, The Journal of experimental medicine.

[18]  R. Rickles,et al.  Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries. , 1994, The EMBO journal.

[19]  D. Baltimore,et al.  SH2 and SH3 domains as molecular adhesives: the interactions of Crk and Abl. , 1994, Trends in biochemical sciences.

[20]  B. Druker,et al.  Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. , 1994, The Journal of biological chemistry.

[21]  S. Ogawa,et al.  A novel signaling molecule, p130, forms stable complexes in vivo with v‐Crk and v‐Src in a tyrosine phosphorylation‐dependent manner. , 1994, The EMBO journal.

[22]  T. Fioretos,et al.  Cellular interactions of CRKL, and SH2-SH3 adaptor protein. , 1994, Cancer research.

[23]  C. Sawyers,et al.  Differential complementation of Bcr-Abl point mutants with c-Myc. , 1994, Science.

[24]  R. Salgia,et al.  Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. , 1994, The Journal of biological chemistry.

[25]  A. Kazlauskas.  Receptor tyrosine kinases and their targets. , 1994, Current opinion in genetics & development.

[26]  T Pawson,et al.  Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.

[27]  L. Lim,et al.  A brain serine/threonine protein kinase activated by Cdc42 and Rac1 , 1994, Nature.

[28]  H. Broxmeyer,et al.  Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway , 1994, The Journal of experimental medicine.

[29]  Nanxin Li,et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.

[30]  G. Burgess,et al.  Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. , 1993, Blood.

[31]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[32]  M. Wigler,et al.  Complex formation between RAS and RAF and other protein kinases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Kazlauskas,et al.  Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal , 1993, Cell.

[34]  O. Witte,et al.  Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  O. Witte,et al.  SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence , 1993, Molecular and cellular biology.

[36]  P Cicchetti,et al.  Identification of a ten-amino acid proline-rich SH3 binding site. , 1993, Science.

[37]  S. Shurtleff,et al.  Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling , 1991, Nature.

[38]  N. Rosenberg,et al.  Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene. , 1991, Molecular and cellular biology.

[39]  G. Daley,et al.  v-abl causes hematopoietic disease distinct from that caused by bcr-abl. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  F. McCormick,et al.  Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  O. Witte,et al.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.

[42]  J. Wang,et al.  Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins , 1991, Molecular and cellular biology.

[43]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Hagemeijer,et al.  A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1990, Leukemia.

[45]  A. Elefanty,et al.  bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. , 1990, The EMBO journal.

[46]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[47]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[48]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[49]  D. Baltimore,et al.  The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization , 1989, Cell.

[50]  O. Witte,et al.  Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells , 1989, Molecular and cellular biology.

[51]  W. On,et al.  Structural characterization of the BCR gene product. , 1989 .

[52]  O. Witte,et al.  The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc , 1989, Molecular and cellular biology.

[53]  D. Baltimore,et al.  N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl. , 1989, The EMBO journal.

[54]  J. Wang,et al.  Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential. , 1989, The EMBO journal.

[55]  J U Gutterman,et al.  The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.

[56]  O. Witte,et al.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Kmiecik,et al.  Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation , 1987, Cell.

[58]  T. Roberts,et al.  Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src , 1987, Cell.

[59]  D. Rennick,et al.  Control of hemopoiesis by a bone marrow stromal cell clone: lipopolysaccharide- and interleukin-1-inducible production of colony-stimulating factors. , 1987, Blood.

[60]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[61]  S. Courtneidge,et al.  Src family protein tyrosine kinases and cellular signal transduction pathways. , 1995, Current opinion in cell biology.

[62]  N. Rosenberg,et al.  The viral and cellular forms of the Abelson (abl) oncogene. , 1988, Advances in virus research.